Helius Medical Technologies, Inc. (HSDT)

NASDAQ: HSDT · IEX Real-Time Price · USD
0.248
-0.002 (-0.80%)
At close: Mar 29, 2023, 4:00 PM
0.240
-0.008 (-3.23%)
Pre-market: Mar 30, 2023, 7:00 AM EDT
-0.8%
Market Cap 7.00M
Revenue (ttm) 787,000
Net Income (ttm) -14.07M
Shares Out 28.21M
EPS (ttm) -1.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 111,282
Open 0.240
Previous Close 0.250
Day's Range 0.240 - 0.260
52-Week Range 0.200 - 3.865
Beta 1.24
Analysts Buy
Price Target 2.72 (+996.77%)
Earnings Date May 11, 2023

About HSDT

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The compan... [Read more]

Industry Medical Devices
Sector Healthcare
CEO Philippe Deschamps
Employees 19
Stock Exchange NASDAQ
Ticker Symbol HSDT
Full Company Profile

Financial Performance

In 2022, HSDT's revenue was $787,000, an increase of 50.77% compared to the previous year's $522,000. Losses were -$14.07 million, -22.39% less than in 2021.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for HSDT stock is "Buy." The 12-month stock price forecast is $2.72, which is an increase of 996.77% from the latest price.

Price Target
$2.72
(996.77% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Helius Medical Technologies, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Class A Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary

NEWTOWN, Pa., March 23, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today that...

6 days ago - GlobeNewsWire

Helius Medical Technologies and HealthTech Connex Announce Exclusive Distribution Agreement for the Portable Neuromodulation Stimulator (PoNS®) Device

-- Agreement extends existing partnership -- -- Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area and will greatly strengthen Helius's presence in the ...

1 week ago - GlobeNewsWire

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

-- Full year 2022 revenue of $0.8 million, an increase of 51% over 2021 -- -- Year-end cash balance of $14.5 million --

2 weeks ago - GlobeNewsWire

Helius Medical Technologies Announces Authorization from Health Canada to Market Portable Neuromodulation Stimulator (PoNS®) Device for the Treatment of Gait Deficit Due to Mild and Moderate Symptoms from Stroke

-- PoNS already approved in Canada for treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury (TBI) and gait deficit due to mild and moderate symptoms from Multiple Sclero...

2 weeks ago - GlobeNewsWire

Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

NEWTOWN, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodula...

3 weeks ago - GlobeNewsWire

Helius Medical Technologies to Present at the 35th Annual ROTH Conference

NEWTOWN, Pa., March 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulat...

3 weeks ago - GlobeNewsWire

Helius Medical Technologies to Showcase PoNS Therapy™ at American Physical Therapy Association's 2023 Combined Sections Meeting

Physical therapists in attendance can enhance their skillset with free on-site PoNS training Physical therapists in attendance can enhance their skillset with free on-site PoNS training

1 month ago - GlobeNewsWire

Helius Medical Technologies, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2022

-- Q4 2022 revenue projected to range from $275,000 to $285,000 -- -- Full year 2022 revenue projected to range from $780,000 to $790,000 -- -- Unaudited year end cash balance of $14.5 million -- NEWT...

2 months ago - GlobeNewsWire

Helius Medical Technologies to Present at the Virtual Q1 Investor Summit Microcap Event, January 26, 2023

NEWTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that ...

2 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. Announces Participation of Neurology Center of New England in its Therapeutic Experience Program

-- Fifth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects' adherence to PoNS ® therapy for gait improveme...

2 months ago - GlobeNewsWire

Helius Extends its Patient Therapy Access Program (PTAP), Bringing the Benefits of its PoNS® Device to More People with Multiple Sclerosis

PTAP Lowers the Cost of PoNS Therapy™ for Qualified Americans PTAP Lowers the Cost of PoNS Therapy™ for Qualified Americans

2 months ago - GlobeNewsWire

Helius Launches UpScript Telehealth e-Commerce Site, Making it Easier for Americans with Multiple Sclerosis to Access Neurotech that can Improve their Ability to Walk

New Partnership with UpScript Provides Access to Care, Delivers PoNS Devices to Doorsteps New Partnership with UpScript Provides Access to Care, Delivers PoNS Devices to Doorsteps

3 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

NEWTOWN, Pa., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced tha...

3 months ago - GlobeNewsWire

5 Winning Stocks Backed by the Overlooked Rising P/E Trick

Want to try an out-of-the-box approach? Tap AMC Entertainment (AMC), Live Nation Entertainment (LYV), CuriosityStream (CURI), Helius Medical Technologies (HSDT) and Vir Biotechnology (VIR).

Other symbols: AMCCURILYVVIR
4 months ago - Zacks Investment Research

Helius Medical Technologies, Inc. (HSDT) Moves to Buy: Rationale Behind the Upgrade

Helius Medical Technologies, Inc. (HSDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near t...

4 months ago - Zacks Investment Research

Helius Medical Technologies, Inc. Reports Third Quarter 2022 Financial Results

-- Total Q3 revenue up 80% over prior year -- -- Cash on hand expected to fund operations through 2023 -- -- Company to host call at 8:30am today -- NEWTOWN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Hel...

4 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. Announces Participation of Dr. Prue Plummer and MGH Institute of Health Professions to its Therapeutic Experience Program

-- Fourth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate impact of subjects' adherence to PoNS® therapy for gait improvement i...

5 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. Announces Participation of Oregon Health & Science University in its Therapeutic Experience Program

-- Third Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects' adherence to PoNS® therapy for gait improvemen...

5 months ago - GlobeNewsWire

Helius to Showcase Innovative PoNS Device at ACRM's 2022 Conference – Demonstrating the Power of Neuromodulation to Help People with MS Improve their Gait

Physical Therapists Who Visit Booth 512 Can Sign Up for Free Online PoNS Therapy™ Training Physical Therapists Who Visit Booth 512 Can Sign Up for Free Online PoNS Therapy™ Training

5 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. to Release Third Quarter 2022 Financial Results on November 14, 2022

NEWTOWN, Pa., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that...

5 months ago - GlobeNewsWire

Helius Salutes Physical Therapists for Their Role in Helping People with MS Improve Their Gait

Company Spotlights its Appreciation to Physical Therapists Trained in its Innovative PoNS Therapy™ in Honor of National Physical Therapy Month Company Spotlights its Appreciation to Physical Therapist...

6 months ago - GlobeNewsWire

Helius Medical Technologies to Present at the ROTH Capital Partners Inaugural Healthcare Opportunities Conference

NEWTOWN, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that...

6 months ago - GlobeNewsWire

Helius Medical Technologies to Present at Upcoming Healthcare Investor Conferences in September

NEWTOWN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that...

7 months ago - GlobeNewsWire

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: CASIHCWB
7 months ago - Benzinga

What Makes Helius Medical Technologies, Inc. (HSDT) a New Buy Stock

Helius Medical Technologies, Inc. (HSDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near t...

7 months ago - Zacks Investment Research